ClinicalTrials.gg
RecruitingNCT06694935Updated Jan 13, 2025

A Phase 1b Study of QX1206 in T2DM Patients With NAFLD

A Phase 1 interventional study of QX1206 in Type 2 Diabetes Mellitus (T2DM) and Non-Alcoholic Fatty Liver Disease (NAFLD), sponsored by 1Globe Health Institute. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-01-13.

Sponsored by 1Globe Health Institute · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 756 studies in Diabetes Mellitus, Type 2 with a site in Canada — 81 open to participants now, 112 under way, 25 of them phase 3. Diabetes Mellitus, Type 2 · Canada.

Planned enrollment
512th of 673
52 · median 227
Started
2025
with 23 others
Phase 1
23 of 756
4 open now
Primary completion
2025-07
later than 10 of 111 live
Registered
695th of 756
by date

Among the 756 studies in Diabetes Mellitus, Type 2 with a site in Canada, this one is the 512th largest by planned enrollment of the 673 interventional ones that give a count, is one of 24 that started in 2025, is one of 23 in phase 1, reaches primary completion later than 10 of the 111 other live ones, and was the 695th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

81 of the 756 studies in Diabetes Mellitus, Type 2 with a site in Canada are open now. Recruiting first, the newest first:

76 more — sign in →

All 81 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 756 studies in Diabetes Mellitus, Type 2 with a site in Canada, or all of them as a file.
02

Study summary

This is an open label phase 1b trial of QX1206 in patients with T2DM and with NAFLD. Laboratory tests and other measurements will be assessed prior to the first dose of study treatment and throughout the study to determine the recommended phase 2 dose. In addition, the preliminary effects of QX1206 on antidiabetic activity and other metabolic parameters will also be evaluated.

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)
  • Non-Alcoholic Fatty Liver Disease (NAFLD)
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written must be obtained and documented
  • 18 years of age and \< 65 years old
  • ≥ 18 kg/m\^2 and \< 45 kg/m\^2
  • T2DM diagnosed per 2021 American Diabetes Association criteria
  • Diagnosis of NAFLD
  • For male or female patients of child producing potential: must agree to use or take measures to avoid pregnancy during the study
  • Women of (WOCBP) must have a negative pregnancy test
  • Serum creatinine \< 1.5× or ≥ 60 ml/min
  • Participating patients must be able to comply with all study requirements and the study center must have appropriate means of ensuring protocol compliance for each participating patient

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled diabetes
  • Patients with an active, serious medical disease that limit activities of daily living
  • Patients with current, significant alcohol consumption or a history of significant alcohol consumption
  • Patients with any of the following clinical laboratory abnormalities at screen and confirmed by a single repeat if deemed necessary:
  • Fasting triglycerides > 500 mg/dL
  • Fasting direct LDL-C > 190 mg/dL
  • > 5.0 × (ULN)
  • ALT > 5.0 × ULN
  • Alkaline phosphatase (ALP) ≥ 2 × ULN
  • > 10.5%
  • Fasting plasma glucose (FPG) > 240 mg/dL (13.3 mmol/L)
  • count \< 140,000/mm\^3
  • Patient takes drugs historically associated with NAFLD and other known hepatotoxins
  • Treatment with drugs (e.g., vitamin E > 400 IU/day) or herbal supplements with potential anti-NAFLD effect
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    QX1206

    Drug: QX1206

Interventions

  • DrugQX1206

    QX1206 will be administered orally before bedtime

06

What researchers measure

Primary outcomes

  1. Recommended Phase 2 Dose (RP2D)

    Time frame: Baseline Day 1 up to Week 12

Secondary outcomes

  1. Hemoglobin A1c (HbA1c)

    Change in HbA1c percentage from baseline with QX1206

    Time frame: 12 Weeks

  2. Fasting plasma glucose (FPG)

    Change in FPG mg/dL from baseline with QX1206

    Time frame: 12 Weeks

  3. Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)

    Change in the HOMA-IR from baseline with QX1206

    Time frame: 12 Weeks

  4. Fasting insulin

    Change in fasting insulin pmol/L from baseline with QX1206

    Time frame: 12 Weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jul 2025, 6 months after the start.

Of 454 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's planned 6 months is above that.

Counting every sponsor, half of 517 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2024
First posted
Nov 19, 2024
StartActual
Jan 6, 2025
Primary completionEst.
Jul 2025
CompletionEst.
Dec 2025
Last update
Jan 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06694935
Lead sponsor
1Globe Health Institute
Responsible party
Sponsor
First posted
Nov 19, 2024
Start date
Jan 6, 2025
Primary completion
Jul 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Jan 13, 2025

Study contacts

1Globe Health Institute
Contact
T2DM-QX1206-1_Study@1globe-usa.com
617-649-1157
Andrew Keates, PhD
study director · 1Globe Health Institute

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion